Since  FDA approval of the use of recombinant insulin (the first biopharmaceutical) in 1982 adoption of biological therapeutics has continued to grow to a market now estimated to be worth over $1.5T. The high specificity and activity of this class of therapeutics, coupled with reduced side effects compared with small synthetic molecules, is continuing to … Continue reading Introducing the Clara™ System for Clarity in Biologics Preparations